DermaSensor, Inc.’s Post

View organization page for DermaSensor, Inc., graphic

4,016 followers

DermaSensor is pleased to announce a groundbreaking publication in the Journal of the American Board of Family Medicine that highlights the impressive performance of our AI-powered spectroscopy device in assessing patients' worrisome moles. Our innovative device is designed to enhance primary care clinicians' ability to accurately detect skin cancer while effectively ruling out benign lesions that may cause patient concern. This study involved three primary care clinicians evaluating 178 skin lesions, demonstrating that the DermaSensor device achieved a sensitivity of 90.0% and a Negative Predictive Value (NPV) of 98.9%. This means it can reliably identify benign lesions, ensuring that patients who need specialist care are referred promptly to a dermatologist. Dr. Nathalie Zeitouni, a leading Mohs surgeon and one of the study's authors, emphasized the importance of early detection: “This research shows that when patients are concerned about suspicious spots on the skin, DermaSensor accurately identifies benign lesions, which helps find malignant cases early”. Read more here > https://lnkd.in/eJvnYwpu #SkinCancerDetection #AI #HealthcareInnovation #PatientCare #DPC #ABFM #JABFM

  • No alternative text description for this image
Hans Hickler

CEO Founder Ellipsis Advisors, Advisor to early stage, mid and large cap C-Level, speaker, podcaster, author

1mo

Amazing!

Like
Reply

To view or add a comment, sign in

Explore topics